PSMA Targeting Ligand Compound for Prostate Cancer Diagnosis and Treatment
Summary
The European Patent Office published patent application EP4431503A1 filed by Chengdu StarRay Therapeutics Co., Ltd. covering ligand compounds that target PSMA (Prostate-Specific Membrane Antigen) for use in prostate cancer diagnosis and treatment. The application includes claims for chelate compounds and their therapeutic and diagnostic applications. The patent is classified under IPC codes C07D 401/12, C07F 5/00, A61K 51/04, and A61P 35/00, covering 37 designated contracting states.
What changed
EPO published international patent application EP4431503A1 for a PSMA (Prostate-Specific Membrane Antigen) targeting ligand compound and chelate for prostate cancer diagnostic and therapeutic applications. The applicant is Chengdu StarRay Therapeutics Co., Ltd. with seven listed inventors. The application covers organic chemistry compounds targeting PSMA antigens, which are overexpressed in prostate cancer cells, enabling both imaging and therapeutic uses.
For pharmaceutical and biotechnology companies, this patent publication represents potential freedom-to-operate considerations for PSMA-targeted radiopharmaceutical development. The designated states cover all European Patent Convention members including DE, FR, GB, IT, ES, NL, CH, and others. Companies developing similar PSMA-targeting compounds for prostate cancer applications should review this publication for potential overlap with their own IP strategies.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
Publication EP4431503A1 Kind: A1 Apr 08, 2026
Applicants
Chengdu StarRay Therapeutics Co., Ltd.
Inventors
ZHONG, Zhiyuan, YUAN, Jiandong, YANG, Jiangtao, HUANGFU, Zhenyuan, SUN, Juan, XU, Bin, TAO, Lei
IPC Classifications
C07D 401/12 20060101AFI20230519BHEP C07F 5/00 20060101ALI20230519BHEP A61K 51/04 20060101ALI20230519BHEP A61P 35/00 20060101ALI20230519BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.